Physician profile
Craig Austin
NPI 1225149982
$4,374.02
in general payments reported to CMS, 2019-2025
29 companies · $475 in 2025
The $475 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $729 · 2020: $173 · 2021: $624 · 2022: $1,000 · 2023: $751 · 2024: $623 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.16 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $875.21 | 2019-2025 | |
| Abbvie INC. | $629.68 | 2019-2025 | Rinvoq, Skyrizi |
| Merz North America, INC. | $431.73 | 2021-2025 | |
| Incyte Corporation | $327.01 | 2021-2024 | Opzelura |
| Janssen Biotech, INC. | $314.58 | 2022-2024 | Tremfya, Stelara, Simponi Aria |
| Amgen INC. | $253.04 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $241.55 | 2019-2025 | Adbry |
| Genzyme Corporation | $190.05 | 2021-2023 | |
| E.R. Squibb & Sons, L.L.C. | $177.91 | 2022-2025 | Sotyktu |
| Allergan, INC. | $156.53 | 2019-2020 | |
| Lilly USA, LLC | $117.54 | 2019-2023 | Taltz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $108.55 | 2019 | |
| Ucb, INC. | $78.98 | 2021-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $58.15 | 2024 | Zoryve |
| Celgene Corporation | $57.49 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $46.90 | 2019-2025 | Aklief |
| Dermavant Sciences, INC. | $38.56 | 2024 | Vtama |
| Vyne Pharmaceuticals INC. | $37.97 | 2020 | |
| Almirall LLC | $37.60 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $32.44 | 2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $26.81 | 2023 | Blu-U, Odomzo |
| Paratek Pharmaceuticals, INC. | $22.12 | 2023 | Nuzyra |
| Biofrontera INC. | $20.57 | 2019 | |
| Merck Sharp & Dohme LLC | $19.89 | 2019 | |
| Botanix Sb INC | $18.54 | 2025 | Sofdra |
| Novartis Pharmaceuticals Corporation | $18.44 | 2023 | |
| Krystal Biotech INC | $15.73 | 2024 | Vyjuvek |
| Mayne Pharma Commercial LLC | $15.11 | 2019 | |
| Organon LLC | $5.34 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Austin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.